83-2270-63　［受注停止］KRIBIOLISA Denosumab （PROLIA） ELISA 1 x 96 wells　KBI1026

特徴

• Description：Enzyme Immunoassay for the quantitative determination of Denosumab in serum, plasma and cell culture supernatant.
• Denosumab （trade names Prolia and Xgeva） is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
• Denosumab is contraindicated in people with low blood calcium levels.
• The most common side effects are joint and muscle pain in the arms or legs.
• Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone （bone resorption）.
• Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs the quantitative sandwich enzyme immunoassay technique.
• Antibodies to Denosumab are pre-coated onto microwells.
• Samples and standards are pipetted into microwells and human Denosumab present in the sample are bound by the capture antibody.
• Then, a HRP （horseradish peroxidase） conjugated anti-Denosumab antibody is pipetted and incubated.
• After washing microwells in order to remove any non-specific binding, the ready to use substrate solution （TMB） is added to microwells and color develops proportionally to the amount of Denosumab in the sample.
• Color development is then stopped by addition of stop solution.
• Absorbance is measured at 450 nm.